

Commercial momentum as Cone Health becomes third U.S. customer

Hospital onboarding to be led by U.S. based Customer Success team

PERTH, Australia, 23 December 2025: Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce its third U.S. commercial customer, with the signing of a commercial agreement with Cone Health for the use of its Salix® platform.

Key Points

- **U.S. foundation partner, Cone Health, becomes Artrya's third U.S. commercial customer**
- **Five-year agreement with a minimum value of US\$0.45M for the use of the Salix® Coronary Anatomy platform, with additional per-scan revenue from Salix® Coronary Plaque module**
- **Salix® to be fully integrated across Cone Health's network of hospitals and cardiology practices**
- **Successfully completes conversion of all three U.S. foundation partners to commercial customers in 2025**

John Konstantopoulos, Co-Founder and CEO of Artrya, commented:

"We are very pleased to secure Cone Health, one of North Carolina's leading healthcare networks, as our third U.S. commercial customer. We have now successfully converted all three of our foundation partners to commercial customers, which highlights the benefits of our partner collaborations to validate the clinical and commercial use of Salix®. This also shows our growing commercial momentum as we move into 2026, where we will focus on growing the use of the Salix® platform and plaque module throughout our customer base."

Dr. Wesley O'Neal, MD, Medical Director of Cardiac CT and Nuclear Cardiology at Cone Health, commented:

"We are delighted to build on our successful collaboration with Artrya and bring this transformative Salix® technology into the clinical workflow across our network. Through this process we can see major benefits in the way that Salix® can provide accurate, point-of-care interpretation of CCTA scans within minutes, enabling our team to deliver faster, more precise diagnoses for our patients. Moving forward we believe this will advance patient care across our network."

Sheryl Booth, Executive Director Heart and Vascular Centre for Cone Health, commented:

"The Cone Health clinical and operating team have worked closely with Artrya and the Salix® platform to assess how this technology can enable us to streamline interpretation, reduce variability, and improve diagnosis at the point of care. The selection of Salix® as our clinical platform, is another step forward to advancing our cardiovascular medicine practice and offering more efficient care for our patients across North Carolina. We were also pleased with the support of the onboarding team, working to train our clinical team and update our patient records and billing systems."

Third commercial customer for clinical use of the Salix® platform

Artrya has signed a five-year commercial agreement with Cone Health, its third U.S. foundation partner, marking another step forward in the Company's accelerating U.S. commercial operations. Under the contract, Salix® Coronary Anatomy will be licensed as a SaaS platform with a fixed monthly subscription fee over a 60-month term, while assessments performed using the Salix® Coronary Plaque module will generate fee-per-scan revenue.

As one of three U.S. foundation partners, Cone Health has worked collaboratively to integrate the Salix® platform following the signing of a strategic partnership agreement in June 2024. This work has involved evaluating the Salix® platform in Cone Health's test workflow and the interaction with both their Picture Archiving and Communication System (PACS) and the Electronic Medical Record (EMR) systems. Cone Health is a leading not-for-profit health system

in North Carolina, with a network of five hospitals, six ambulatory care centres, three outpatient surgery centres, eight urgent care centres and more than 120 physician practices.

The onboarding of Cone Health will be managed and supported by Artrya's recently established Customer Success team in Atlanta, Georgia. The ability of Artrya's U.S. team to provide real-time customer management, integration and support by is a key strategy to build successful U.S. commercial operations.

Material terms of the agreement

The full details of the Commercial Agreement are commercial in confidence, with the material points as follows:

- Commercial SaaS Licence Agreement for non-exclusive use of the Salix® Coronary Anatomy platform for clinical use
- Monthly subscription fee over the duration for use of the Salix® Coronary Anatomy platform
- Fee per scan revenue to be charged for use of Salix® Coronary Plaque which is eligible for U.S. reimbursement under a Category 1 CPT code
- Five-year term for the agreement with standard provisions for events of default
- Termination with 30 days' notice with no cancellation fees
- Customary terms include security and privacy protocols, support levels, software upgrades.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

For more information:

Corporate Enquiries

John Konstantopoulos
Co-Founder and Chief Executive Officer
Tel: +61 8 6478 7816
Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger
Hawkesbury Partners
Tel: +61 499 100 038 or +61 410 577 155
Email: investors@artrya.com